Key result
The review highlights newly discovered functions of the renin angiotensin system, particularly the alternate RAS system, and its potential for new pharmacologic interventions in cardiovascular disease.
The discovery of the 'alternate' renin-angiotensin system involving angiotensin 1-7 offers new insights into cardiovascular homeostasis and potential novel pharmacological targets.
The renin angiotensin system (RAS) is thought to be the body's main vasoconstrictor system, with physiological effects mediated via the interaction of angiotensin II with angiotensin I receptors (the "classic" RAS model). However, since the discovery of the heptapeptide angiotensin 1-7 and the development of the concept of the "alternate" RAS system, with its ability to reduce arterial blood pressure, our understanding of this physiologic system has changed dramatically. In this review, we focus on the newly discovered functions of the RAS, particularly the potential clinical significance of these developments, especially in the realm of new pharmacologic interventions for treating cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Farag et al. (2015) conducted a review in Cardiovascular disease. Renin angiotensin system (RAS) targeted pharmacologic interventions was evaluated. The review highlights newly discovered functions of the renin angiotensin system, particularly the alternate RAS system, and its potential for new pharmacologic interventions in cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: